SION Sionna Therapeutics, Inc.
Price Chart
Executive Summary
Sionna reported Q1 2026 GAAP EPS of -$0.60, a 3.2% beat vs consensus of -$0.62, but net loss widened to $26.8M from $16.5M a year ago on higher R&D and G&A spending. The key catalyst is the on-track summer 2026 topline data from the Phase 2a PreciSION CF trial and Phase 1 dual-combination trial, which will determine whether SION-719 can expand CF treatment options. Cash of $289.9M funds operations into 2028, removing near-term dilution risk.
Actionable Insight
The stock will trade on Phase 2a and Phase 1 topline data catalysts this summer, not on Q1 financials. Watch for sweat chloride data from PreciSION CF — a clinically meaningful reduction would validate SION-719's mechanism and likely drive a re-rating. The 88% analyst buy rating and $2.1B market cap already price in some optimism; a data miss would be severely punished given the binary nature of the readout.
Key Facts
- Q1 2026 GAAP EPS -$0.60 vs consensus -$0.62 (3.2% beat)
- Net loss widened to $26.8M from $16.5M YoY on higher R&D ($19.0M vs $13.7M) and G&A ($10.6M vs $6.0M)
- Phase 2a PreciSION CF trial of SION-719 enrollment completed; topline data expected summer 2026
- Phase 1 dual-combination trial of SION-451 with SION-2222 and SION-109 on track for summer 2026 topline data
- Cash, cash equivalents and marketable securities $289.9M; expected to fund operations into 2028
- No revenue reported (pre-commercial biotech)
Financial Impact
Net loss of $26.8M in Q1 2026 vs $16.5M in Q1 2025; cash burn rate ~$10M/month
Risk Factors
- Phase 2a topline data could fail to show clinically meaningful sweat chloride reduction, undermining the NBD1 stabilizer thesis
- Cash burn rate increased 62% YoY; if data disappoints, financing risk emerges despite current runway into 2028
- Insider selling of $31.7M in last 30 days may signal lack of confidence ahead of data readout
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3292667 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 30, 2026
11d ago
|
Insider Cluster
| $40.90 $35.37 | ▼ −13.52% | ▼ −10.77% | $33.69 (−17.63%) |
|
May 29, 2026
11d ago
|
144
| $40.90 $35.37 | ▲ +13.52% | ▲ +10.77% | $33.69 (+17.63%) |
|
May 12, 2026
28d ago
|
8-K
| $40.94 $39.24 | ▼ −4.15% | ▼ −4.23% | $33.69 (−17.71%) |
|
May 12, 2026
28d ago
|
Press Release
| $40.94 $39.24 | ▼ −4.15% | ▼ −4.23% | $33.69 (−17.71%) |
|
May 7, 2026
4w ago
|
Insider Cluster
| $43.31 $43.12 | ▲ +0.44% | ▲ +1.94% | $33.69 (+22.21%) |
|
Apr 27, 2026
6w ago
|
Press Release
| $39.21 $40.45 | ▲ +3.16% | ▲ +2.76% | $33.69 (−14.08%) |
|
Apr 16, 2026
7w ago
|
Insider Cluster
| $45.24 $38.35 | ▲ +15.23% | ▲ +16.21% | $33.69 (+25.53%) |
|
Apr 15, 2026
8w ago
|
Insider Cluster
| $45.09 $43.20 | ▲ +4.19% | ▲ +5.83% | $33.69 (+25.28%) |
|
Mar 2, 2026
14w ago
|
Press Release
| $33.92 $37.53 | ▲ +10.64% | ▲ +11.85% | $33.69 (−0.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access